- Home
- XPEV vs HOLX Comparison
XPEV vs HOLX Comparison
Compare XPEV & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEV | HOLX |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | China | United States |
| Employees | 19884 | N/A |
| Industry | Auto Manufacturing | Medical Electronics |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 16.9B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | XPEV | HOLX |
|---|---|---|
| Price | $15.85 | $76.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 13 |
| Target Price | $23.08 | ★ $77.89 |
| AVG Volume (30 Days) | 4.8M | ★ 25.5M |
| Earning Date | 05-20-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | ★ $4,100,500,000.00 |
| Revenue This Year | $25.76 | $4.74 |
| Revenue Next Year | $25.98 | $5.03 |
| P/E Ratio | ★ N/A | $96.23 |
| Revenue Growth | N/A | ★ 1.74 |
| 52 Week Low | $15.38 | $51.90 |
| 52 Week High | $28.20 | $76.07 |
Technical Indicators
Market Signals| Indicator | XPEV | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 36.76 | 69.09 |
| Support Level | $15.38 | $75.10 |
| Resistance Level | $18.38 | N/A |
| Average True Range (ATR) | 0.47 | 0.19 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 5.37 | 95.19 |
Price Performance
Historical ComparisonAbout XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold about 430,000 EVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.